Lineage Cell Therapeutics Inc LCTX:NYSE American

Last Price$1.25AMEX Closing Price as of 4:10PM ET 5/20/22
AMEX 15-minute delayed Bid/Ask Quotes
Today's Change+0.01(0.81%)
Bid (Size)$1.18 (2)
Ask (Size)$1.27 (6)
Day Low / High$1.20 - 1.29
Volume429.9 K

View Biotechnology IndustryPeer Comparison as of 05/20/2022


Lineage Cell Therapeutics Inc ( NYSE MKT LLC )

Price: $1.25
Change: +0.01 (0.81%)
Volume: 429.9 K
4:10PM ET 5/20/2022

Cogent Biosciences Inc ( NASDAQ )

Price: $4.73
Change: +0.17 (3.73%)
Volume: 253.3 K
4:00PM ET 5/20/2022

Altimmune Inc ( NASDAQ )

Price: $5.02
Change: +0.20 (4.15%)
Volume: 569.9 K
4:00PM ET 5/20/2022

Personalis Inc ( NASDAQ )

Price: $4.43
Change: +0.05 (1.14%)
Volume: 455.3 K
4:00PM ET 5/20/2022

Athersys Inc ( NASDAQ )

Price: $0.26
Change: -0.50 (65.54%)
Volume: 45.6 M
4:00PM ET 5/20/2022

Read more news Recent News

-- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Posts Q1 Revenue $5.2M, vs. Street Est of $8.9M
4:18PM ET 5/12/2022 MT Newswires


Lineage Cell Therapeutics Says Cancer Research UK Completes Enrollment for Phase 1 Study of VAC2 Cancer Vaccine
9:37AM ET 4/13/2022 MT Newswires

Lineage Cell Therapeutics (LCTX) said Wednesday that Cancer Research UK has completed enrollment for a phase 1 trial of VAC2 in non-small cell lung cancer....

-- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $4.3M
4:09PM ET 3/10/2022 MT Newswires


Insider Sell: Lineage Cell Therapeutics
6:18AM ET 12/31/2021 MT Newswires

Gary S. Hogge, Senior Vice President, Clinical & Medical Affairs, on December 28, 2021, sold 539,283 shares in Lineage Cell Therapeutics (LCTX) for...

Company Profile

Business DescriptionLineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Ca View company web site for more details
Address2173 Salk Avenue
Carlsbad, California 92008-7354
Number of Employees79
Recent SEC Filing05/12/20228-K
President, Chief Executive Officer & DirectorBrian M. Culley
Chief Financial & Accounting OfficerKevin L. Cook
Senior Vice President-Clinical & Medical AffairsGary S. Hogge
Global Head-Research & DevelopmentFran├žois Binette

Company Highlights

Price Open$1.24
Previous Close$1.24
52 Week Range$1.10 - 3.00
Market Capitalization$212.2 M
Shares Outstanding169.7 M
SectorHealth Technology
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.25
Beta vs. S&P 500N/A
Revenue$1.4 M
Net Profit Margin-1,104.13%
Return on Equity-37.79%

Analyst Ratings as of 11/29/2021

Consensus RecommendationConsensus Icon
Powered by Factset